Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1Phase 1/2 1

Status

Completed 3Terminated 2

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Sarcoma 1Dermatologic 1

Conditions

Hodgkin Disease 45Lymphoma 22Hematologic Diseases 17Lymphoma, Large-Cell, Anaplastic 15Lymphoma, Non-Hodgkin 11Recurrence 9Lymphoma, T-Cell 8Lymphoma, T-Cell, Cutaneous 6Lymphoma, T-Cell, Peripheral 5Mycosis Fungoides 3Lymphoma, Primary Cutaneous Anaplastic Large Cell 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, B-Cell 3Leukemia, Myeloid, Acute 3Sezary Syndrome 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Myelodysplastic Syndromes 2Lymphomatoid Papulosis 2Enteropathy-Associated T-Cell Lymphoma 2Dendritic Cell Sarcoma, Interdigitating 2Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Kaposi 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasms, Germ Cell and Embryonal 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Melanoma 1

Interventions

Rituximab 47Cyclophosphamide 26fludarabine 13ibrutinib 12Doxorubicin 11Vincristine 10Etoposide 10Cytarabine 10Prednisone 9Bortezomib 9pembrolizumab 7fludarabine phosphate 6Lenalidomide 6Inotuzumab Ozogamicin 6obinutuzumab 5Mycophenolic Acid 5Melphalan 5Carmustine 5tositumomab I-131 4ibritumomab tiuxetan 4Tacrolimus 4Prednisolone 4Methotrexate 4Gemcitabine 4Bendamustine Hydrochloride 4Antilymphocyte Serum 4tocilizumab 3tazemetostat 3Whole-Body Irradiation 3Vorinostat 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Lymphoma, B-Cell × Brentuximab Vedotin × Clear all
NCT01990534 2021-04-09

A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma

Takeda

Phase 4 Completed
60 enrolled 21 charts
Lymphoid

Hematologic Diseases, Hodgkin Disease, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Recurrence, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT01421667 2016-11-28

A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma

Seagen Inc.

Phase 2 Completed
176 enrolled 30 charts
Lymphoid

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00051597 2011-10-12

A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies

Seagen Inc.

Phase 1/2 Completed
70 enrolled
DermatologicLymphoidSarcoma

Hodgkin Disease, Sarcoma, Kaposi, Lymphoma, B-Cell, Lymphoma, T-Cell, Cutaneous, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡